Every 8-K that Lixte Biotechnology Holdings, Inc. (LIXT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LIXT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LIXT filings page.
Nomad Power Solutions, Inc. announced that its common stock is now available for options trading on the Cboe Options Exchange under the symbol NMAD. The company’s common stock will continue to trade on the Nasdaq Stock Market under the same ticker.
Chief Executive Officer Geordan Pursglove stated that the launch of options trading is a meaningful step in building the company’s public markets profile and may increase visibility among institutional and retail investors. Options trading, with a full range of standard expiration dates and strike prices, is expected to enhance investor participation, liquidity, and flexibility.
Nomad Power Solutions, Inc. reported a major upgrade to its Voyager mobile energy storage fleet, increasing standard usable capacity on the Voyager Eagle and Falcon to 2.025 MWh each and on the Voyager Hawk to 1.0 MWh. This delivers more than 50% additional energy per unit while keeping the trailer footprint, rated power output, and sub-one-hour deployment time unchanged, and will apply to all new Voyager units. The design uses prismatic lithium iron phosphate (LFP) packs from Octillion Power Systems to achieve higher energy density for data center and hyperscale customers who need more backup runtime without expanding site footprint.
Lixte Biotechnology Holdings, Inc. has completed its merger with NOMAD Transportable Power Systems, making NOMAD a wholly owned subsidiary and shifting the business toward mobile, utility-grade battery energy storage systems.
As merger consideration, NOMAD stockholders received 2,992,041 shares of common stock and 50,366.07 shares of new Series D Non-Voting Convertible Preferred Stock, which are convertible into up to 50,366,070 common shares at a $1.00 conversion price after stockholder approval. The company is changing its name to Nomad Power Solutions, Inc. effective July 3, 2026, and its NASDAQ ticker from LIXT to NMAD effective July 6, 2026.
The Series D Preferred Stock carries a $1,000 liquidation value per share and will accrue a 7% annual cash dividend, payable quarterly, if required stockholder approval is not obtained within one year. Lixte’s board also appointed NOMAD CEO John Travaglini as a director and approved bylaw and charter changes to support the new capital structure and governance. Registration rights and stockholder support agreements were entered into, and the company will seek stockholder approval for conversion of the preferred stock, an increase in authorized shares, and director elections at a meeting expected around September 4, 2026.
LIXTE Biotechnology Holdings, Inc. entered into a secured financing tied to its planned acquisition of NOMAD Transportable Power Systems. The company issued a $6.5 million Secured Promissory Note to NOMAD, secured by a first-priority security interest in substantially all of NOMAD’s assets.
The note’s proceeds will repay NOMAD’s existing loan with BPCP Investment Holdings and support NOMAD’s working capital and general corporate purposes as it scales to meet an active order pipeline. The note matures in 30 days, with automatic 30‑day extensions while the merger agreement remains in effect, and its principal will be offset against merger consideration at closing.
If the merger is terminated due to a breach by LIXTE, the note becomes repayable within six months; if terminated due to a breach by NOMAD, it is due within three days. LIXTE expects the NOMAD acquisition to close on or about July 1, 2026, after which the combined company will be renamed NOMAD Power Solutions, Inc. and trade under a new ticker symbol on Nasdaq.
LIXTE Biotechnology Holdings, Inc. signed a definitive Merger Agreement to acquire 100% of NOMAD Transportable Power Systems, a leader in mobile, utility-grade battery energy storage systems. Merger Sub will merge into NOMAD, which will become a wholly owned subsidiary, and the combined company plans to be renamed NOMAD Power Solutions.
At closing, NOMAD stockholders will receive a pro rata share of up to 50,500 shares of Series D Convertible Preferred Stock, with a $1,000 original issue price per share and convertible into up to 50,500,000 shares of common stock at $1.00 per share, plus up to 3,000,000 shares of common stock. The preferred stock will be non-voting until stockholders approve its conversion and an increase in authorized shares.
The merger is subject to conditions, including LIXTE having at least $16.5 million in unrestricted cash, Nasdaq listing of the Exchange Common Shares, and board changes adding NOMAD designees. NOMAD has shown rapid growth, with management citing approximately 175% revenue growth in 2025 and a projected approximately 135% increase in 2026, driven by strong demand for mobile, utility-grade BESS.
Lixte Biotechnology Holdings, Inc. completed a registered direct offering of 2,366,503 shares of common stock and Pre-Funded Warrants to purchase 258,859 shares, generating gross proceeds of approximately $16.6 million before expenses. The securities were priced at $6.31 per share of common stock and $6.30 per Pre-Funded Warrant.
The Pre-Funded Warrants are immediately exercisable at $0.0001 per share and remain exercisable until fully exercised. The transaction, conducted under an effective shelf registration statement on Form S-3, closed on June 4, 2026, and the company plans to use the net proceeds for general corporate purposes and working capital.
LIXTE Biotechnology Holdings is undertaking a major strategic shift, repositioning itself as an AI energy infrastructure equipment and services platform focused on supplying power solutions for AI and hyperscale data centers. The company highlights a widening gap between North American electricity demand and generation capacity, citing a projected 224 gigawatt increase in summer peak demand over the next decade and recent reliability alerts to frame the opportunity.
As part of this transformation, LIXTE plans to seek a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations that are developing cancer therapies and proton therapy systems. The company expects to maintain its Nasdaq listing under the symbol LIXT while it executes this pivot and pursues strategic acquisitions and partnerships in advanced generation technologies.
LIXTE also appointed Stuart D. Porter to its Board of Directors, effective May 29, 2026, with a term expiring at the 2026 annual meeting. Porter is the Founder, Managing Partner, Chief Executive Officer and Chief Investment Officer of Denham Capital, with over 29 years of senior investment experience and oversight of more than $12 billion of invested and committed capital across energy and energy-transition sectors, including a roughly 10 gigawatt pipeline of AI data-center-oriented power generation opportunities.
Lixte Biotechnology Holdings, Inc. reported that on April 15, 2026, its Compensation Committee canceled certain stock options held by key officers and directors and replaced them with fully vested restricted share units (RSUs) under the company’s 2020 Stock Incentive Plan.
The chief executive officer had 350,000 options canceled and received 350,000 RSUs, the chief financial officer had 50,000 options canceled and received 50,000 RSUs, and four directors each had 25,000 options canceled and received 25,000 RSUs. Each RSU entitles the holder to one share of common stock, and the committee stated that this change is intended to provide a more effective retention and incentive mechanism.
Lixte Biotechnology Holdings, Inc. updated its executive compensation by amending the employment agreement of Chief Executive Officer Geordan Pursglove. Effective January 1, 2026, his annual base salary increased from $240,000 to $360,000, as approved by the Compensation Committee and Board of Directors. The salary Amendment, dated March 18, 2026, is filed as Exhibit 10.1 and incorporated by reference into this report.
Lixte Biotechnology Holdings entered into an Amended and Restated Share Exchange Agreement with its subsidiary Liora Technologies Europe and Orbit Capital, dated March 6, 2026 and effective as of November 21, 2025. This agreement consolidates prior arrangements into a single structure.
Under earlier agreements, Lixte had acquired 100% of Liora, issued 2,700 shares of Series C Preferred Stock to Orbit and entered a royalty agreement, which was later terminated. Orbit then exchanged those preferred shares for 700,000 shares of Lixte common stock and reacquired a 20% ownership interest in Liora. The new agreement is intended to reflect these combined transactions and the parties’ agreed ownership structure.
LIXTE Biotechnology Holdings, Inc. entered into an Allocation Deed and a Consultancy Agreement with its subsidiary Liora Technologies Europe Ltd. and consultant Sidney Braun. Braun becomes CEO and a director of Liora, with a GBP 50,000 signing bonus and a GBP 25,000 monthly retainer, both exclusive of VAT.
Under the Allocation Deed, Braun is entitled to 20% of the net purchase price if there is a sale of Liora or any Liora successor. LIXTE also issued a press release highlighting Braun’s healthcare background and Liora’s LiGHT System proton therapy technology for cancer treatment.
Lixte Biotechnology Holdings (LIXT) completed a share exchange to acquire all shares of Liora Technologies Europe Ltd., which owns the LIGHT proton-based radiotherapy assets previously acquired from Advanced Oncotherapy. As consideration, Lixte will issue 2,700 shares of Series C Preferred Stock, convertible into 2,700,000 common shares (subject to a 19.99% cap until shareholder approval), pay 10.56 Bitcoin, 300 Ethereum, and $440,000 in cash, and enter a royalty agreement. The royalty entitles the seller to 10% of Net Revenue from the LIGHT equipment, up to a $45,000,000 cap, with quarterly calculations and audit rights. The new Series C Preferred Stock is non‑voting, non‑dividend bearing, convertible at a 1,000:1 ratio into common stock, and carries ownership limits tied to Nasdaq shareholder approval requirements.